

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Sophie Bignon et al.

Application No.: 10/580,035

Confirmation No.: 8924

Filed: April 10, 2007

Art Unit: 1647

For: PHARMAEUTICAL FORMULATIONS FOR
THE PROLONGED RELEASE OF
INTERLEUKINS AND THEIR THERAPEUTIC
APPLICATIONS

Examiner: C. M. WOODWARD

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be considered for this application.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR § 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Similarly, copies of Office Actions issued in commonly-owned U.S. patent applications directed to similar subject matter, also stored and available to the Examiner in electronic form in the Office's IFW system, have not been submitted. 69 FR 56481, 56510, Sept. 21, 2004.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Credit Card in the amount of \$180.00 covering the fees set forth in 37 C.F.R. § 1.17(p). The U.S. Patent and Trademark Office is authorized to charge any additional fees that may be required in conjunction with this submission to Deposit Account Number 50-2228, under Order No. 022290.0158PTUS.

Dated: October 1, 2010

Respectfully submitted,

By /Lacy L. Kolo/
Lacy L. Kolo
Registration No.: 55,340
PATTON BOGGS LLP
8484 Westpark Drive, 9th Floor
McLean, Virginia 22102
(703) 744-8000
(703) 744-8001 (Fax)
Attorney for Applicants